Abstract
PurposeGlioma is the most prevalent malignant form of brain tumors, with a dismal prognosis. Currently, cancer immunotherapy has emerged as a revolutionary treatment for patients with advanced highly aggressive therapy-resistant tumors. However, there is no effective biomarker to reflect the response to immunotherapy in glioma patient so far. So we aim to assess the clinical predictive value of FCER1G in patients with glioma.MethodsThe expression level and correlation between clinical prognosis and FER1G levels were analyzed with the data from CGGA, TCGA, and GEO database. Univariate and multivariate cox regression model was built to predict the prognosis of glioma patients with multiple factors. Then the correlation between FCER1G with immune cell infiltration and activation was analyzed. At last, we predict the immunotherapeutic response in both high and low FCER1G expression subgroups.ResultsFCER1G was significantly higher in glioma with greater malignancy and predicted poor prognosis. In multivariate analysis, the hazard ratio of FCER1G expression (Low versus High) was 0.66 and 95 % CI is 0.54 to 0.79 (P < 0.001), whereas age (HR = 1.26, 95 % CI 1.04–1.52), grade (HR = 2.75, 95 % CI 2.06–3.68), tumor recurrence (HR = 2.17, 95 % CI 1.81–2.62), IDH mutant (HR = 2.46, 95 % CI 1.97–3.01) and chemotherapeutic status (HR = 1.4, 95 % CI 1.20–1.80) are also included. Furthermore, we illustrated that gene FCER1G stratified glioma cases into high and low FCER1G expression subgroups that demonstrated with distinct clinical outcomes and T cell activation. At last, we demonstrated that high FCER1G levels presented great immunotherapeutic response in glioma patients.ConclusionsThis study demonstrated FCER1G as a novel predictor for clinical diagnosis, prognosis, and response to immunotherapy in glioma patient. Assess expression of FCER1G is a promising method to discover patients that may benefit from immunotherapy.
Highlights
Glioma is served as the most prevalent malignant tumor in central nervous system, which accounts for more than 70 % of intracranial tumors with high degree of malignancy [1, 2]
We demonstrated that high FCER1G levels presented great immunotherapeutic response in glioma patients
Assess expression of FCER1G is a promising method to discover patients that may benefit from immunotherapy
Summary
Glioma is served as the most prevalent malignant tumor in central nervous system, which accounts for more than 70 % of intracranial tumors with high degree of malignancy [1, 2]. Arising from glia cells, gliomas can be subdivided into a broad category of tumors, such as astrocytoma, oligodendroglioma, and glioblastoma (GBM). Regardless of tumor aggressiveness and malignancy, the average median time of overall survival is only 12–18 months [3, 4]. Xu et al Cancer Cell Int (2021) 21:103 of therapies are currently available, including surgery, radiotherapy, chemotherapy and immunotherapy, they still remain a low survival. Therapeutic response rely on intra-tumoral heterogeneity and intricacy programmed by genetic and epigenetic effectors. Aggressive therapies compromised the patient’s life quality and drives harmful side effects. Great understanding of the biological behavior and mechanism underlying tumor progression is essential to improve clinical diagnosis and therapeutic prognosis, even for the development of novel effective therapies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
